Our studies support the idea that direct targeting of leptin signaling pathways in the CNS can circumvent a potential leptin transporter defect and, hence, could have therapeutic potential in the treatment of NAFLD. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.